Published in Circ Res on January 29, 2004
Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 2.74
Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev (2009) 1.90
Deletion of Hyaluronan Synthase 3 Inhibits Neointimal Hyperplasia in Mice. Arterioscler Thromb Vasc Biol (2015) 1.40
Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest (2006) 1.29
Abscisic acid released by human monocytes activates monocytes and vascular smooth muscle cell responses involved in atherogenesis. J Biol Chem (2009) 1.04
Hyaluronan and hyaluronan binding proteins are normal components of mouse pancreatic islets and are differentially expressed by islet endocrine cell types. J Histochem Cytochem (2012) 0.88
Substrate-induced phenotypic switches of human smooth muscle cells: an in vitro study of in-stent restenosis activation pathways. J R Soc Interface (2010) 0.84
Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening. J Cell Mol Med (2009) 0.82
Synthesis of hyaluronan in oesophageal cancer cells is uncoupled from the prostaglandin-cAMP pathway. Br J Pharmacol (2009) 0.81
Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts. Br J Pharmacol (2011) 0.77
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype. J Cardiovasc Pharmacol (2016) 0.75
Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res (1999) 2.51
Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem (2001) 2.40
Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy (2004) 2.07
Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol (2007) 1.91
Biglycan is required for adaptive remodeling after myocardial infarction. Circulation (2008) 1.72
Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs (2007) 1.52
Premature trypsinogen activation during cerulein pancreatitis in rats occurs inside pancreatic acinar cells. Pancreas (1998) 1.45
Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol (1997) 1.45
Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation (2003) 1.43
Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res (1999) 1.43
[Prevention of reinfarction with 100 mg or 30 mg aspirin daily?]. Z Kardiol (1995) 1.38
The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro. Naunyn Schmiedebergs Arch Pharmacol (1981) 1.28
Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer (2007) 1.27
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum (1998) 1.26
Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol (2006) 1.18
Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet (1999) 1.16
Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets (2001) 1.14
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol (2001) 1.14
Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost (2011) 1.11
Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension (1995) 1.09
Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin. Eur J Pharmacol (1978) 1.08
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis (2003) 1.07
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol (2004) 1.06
Selective inhibition of cyclooxygenase 2. Biochem Pharmacol (1994) 1.06
Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res (1984) 1.04
Cyclic GMP mediates SIN-1-induced inhibition of human polymorphonuclear leukocytes. Eur J Pharmacol (1990) 1.04
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost (2010) 1.01
Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol (2001) 1.00
Epac inhibits migration and proliferation of human prostate carcinoma cells. Br J Cancer (2009) 0.99
Generation of the isoprostane 8-epi-prostaglandin F2alpha in vitro and in vivo via the cyclooxygenases. J Pharmacol Exp Ther (1997) 0.99
Differential expression of mucins and trefoil peptides in native epithelium, Barrett's metaplasia and squamous cell carcinoma of the oesophagus. J Cancer Res Clin Oncol (1999) 0.99
Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol (1999) 0.98
Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol (1999) 0.97
Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem (2000) 0.97
Reduction of infarct size by selective stimulation of prostaglandin EP(3)receptors in the reperfused ischemic pig heart. J Mol Cell Cardiol (2000) 0.97
Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg (2001) 0.97
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus (2007) 0.96
The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer (2006) 0.96
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol (2010) 0.96
Prostacyclin rather than endogenous nitric oxide is a tissue protective factor in myocardial ischemia. Am J Physiol (1992) 0.95
Differential regulation of hyaluronic acid synthase isoforms in human saphenous vein smooth muscle cells: possible implications for vein graft stenosis. Circ Res (2005) 0.95
Differential effects of vasodilatory prostaglandins on focal adhesions, cytoskeletal architecture, and migration in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol (2004) 0.95
PGD2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils. Eicosanoids (1991) 0.94
Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia. J Pharmacol Exp Ther (1981) 0.94
Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int (1999) 0.93
Prostaglandin D2 (PGD2)--a potent coronary vasoconstrictor agent in the guinea pig isolated heart. Naunyn Schmiedebergs Arch Pharmacol (1978) 0.93
Squamous cell carcinoma and Zenker diverticulum. Dis Esophagus (2007) 0.93
Achalasia-associated squamous cell carcinoma of the esophagus: flow-cytometric and histological evaluation. Gastroenterology (1995) 0.93
Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res (2000) 0.93
Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol (1998) 0.93
Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous-cell carcinoma. Int J Cancer (1999) 0.93
Polymorphisms in methionine synthase (A2756G) and cystathionine beta-synthase (844ins68) and susceptibility to carcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol (2007) 0.92
Preservation of ischemic myocardium by pinane thromboxane A2. Am J Physiol (1980) 0.92
The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin. Br J Pharmacol (1995) 0.91
The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue. Arzneimittelforschung (1982) 0.90
Cytotoxic enzyme release and oxygen centered radical formation in human neutrophils are selectively inhibited by E-type prostaglandins but not by PGI2. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.90
Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol (2001) 0.90
PGI2 inhibits ischemia-induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator. Thromb Res (1981) 0.90
Retinoblastoma-protein (prb) expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer (1999) 0.89
Distribution of cell populations with DNA aneuploidy and p53 protein expression in ulcerative colitis. Eur J Gastroenterol Hepatol (1997) 0.88
Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury. J Pharmacol Exp Ther (1993) 0.87
Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun (1994) 0.87
Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol (1999) 0.87
Thromboxane A2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen. Eur J Pharmacol (1997) 0.87
Loss of expression of the beta subunit of soluble guanylyl cyclase prevents nitric oxide-mediated inhibition of DNA synthesis in smooth muscle cells of old rats. Circ Res (2000) 0.87
Plasma exchanges in frequently recurrent hemolytic-uremic syndrome in a child. Int J Pediatr Nephrol (1983) 0.87
Type I gaucher disease: extraosseous extension of skeletal disease. Skeletal Radiol (2000) 0.87
CT appearance of a renal aspergilloma in a patient with the acquired immunodeficiency syndrome. Urol Int (1999) 0.86
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus. BMC Cancer (2001) 0.86
PDGF-induced Akt phosphorylation does not activate NF-kappa B in human vascular smooth muscle cells and fibroblasts. FEBS Lett (2000) 0.86
Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. Pflugers Arch (2001) 0.86
Prostaglandin D2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ Res (1992) 0.86
Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Curr Med Chem (2000) 0.86
Prostacyclin rather than nitric oxide lowers human umbilical artery tone in vitro. Eur J Obstet Gynecol Reprod Biol (1992) 0.86
Interclonal heterogeneity in a human epithelioid-sarcoma cell line (GRU-1). Int J Cancer (1994) 0.86
Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int (2001) 0.85
Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol (1998) 0.85
Expression, function, and regulation of E-type prostaglandin receptors (EP3) in the nonischemic and ischemic pig heart. Circ Res (1997) 0.84
Prostaglandin E2 stimulates sodium reabsorption in MDCK C7 cells, a renal collecting duct principal cell model. Prostaglandins Leukot Essent Fatty Acids (2003) 0.84
Thrombin-induced mitogenesis in coronary artery smooth muscle cells is potentiated by thromboxane A2 and involves upregulation of thromboxane receptor mRNA. Circulation (1998) 0.84
Increased prostacyclin release from perfused hearts of acutely diabetic rats. Diabetologia (1980) 0.84
Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. Br J Clin Pharmacol (1993) 0.84
Cardioprotective actions of pentoxifylline in an animal model of acute myocardial ischaemia. Br J Pharmacol (1984) 0.84
Prostacyclin-induced coronary vasodilation. Interactions with adenosine, cyclic AMP and energy charge in the rat heart in vitro. Eur J Pharmacol (1980) 0.84
Nitrovasodilator-induced inhibition of LTB4 release from human PMN may be mediated by cyclic GMP. Eicosanoids (1990) 0.83
Parathyroid carcinoma: problems in diagnosis and the need for radical surgery even in recurrent disease. Eur J Surg Oncol (2001) 0.83
Gaucher disease of the spleen: CT and MR findings. Abdom Imaging (2000) 0.83
Cultured arterial smooth muscle cells maintain distinct phenotypes when implanted into carotid artery. Arterioscler Thromb Vasc Biol (2001) 0.83
E-type prostaglandins but not iloprost inhibit platelet activating factor-induced generation of leukotriene B4 by human polymorphonuclear leukocytes. Br J Pharmacol (1989) 0.83
Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Clin Pharmacol Ther (2001) 0.83